{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:11:59Z","timestamp":1770963119101,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol Suppl"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s11789-019-00099-z","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T01:29:20Z","timestamp":1551835760000},"page":"45-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Lipoprotein(a) and proprotein convertase subtilisin\/kexin type\u00a09 inhibitors"],"prefix":"10.1007","volume":"14","author":[{"given":"U.","family":"Julius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tselmin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Schatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. R.","family":"Bornstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,5]]},"reference":[{"issue":"2","key":"99_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","volume":"71","author":"S Tsimikas","year":"2018","unstructured":"Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM et al (2018) NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J\u00a0Am Coll Cardiol 71(2):177\u2013192. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2017.11.014","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"99_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1161\/CIRCRESAHA.116.310272","volume":"120","author":"M Sharma","year":"2017","unstructured":"Sharma M, Redpath GM, Williams MJ, McCormick SP (2017) Recycling of apolipoprotein(a) after PlgRKT-mediated endocytosis of lipoprotein(a). Circ Res 120(7):1091\u20131102. \n                    https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.310272","journal-title":"Circ Res"},{"key":"99_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s11789-017-0085-0","author":"R Schulz","year":"2017","unstructured":"Schulz R, Schluter KD (2017) PCSK9 targets important for lipid metabolism. Clin Res Cardiol Suppl. \n                    https:\/\/doi.org\/10.1007\/s11789-017-0085-0","journal-title":"Clin Res Cardiol Suppl"},{"issue":"4","key":"99_CR4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","volume":"135","author":"G Reyes-Soffer","year":"2017","unstructured":"Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R et al (2017) Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans. Circulation 135(4):352\u2013362. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.025253","journal-title":"Circulation"},{"issue":"6","key":"99_CR5","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S (2017) A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J\u00a0Am Coll Cardiol 69(6):692\u2013711. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2016.11.042","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"99_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa043175","volume":"353","author":"S Tsimikas","year":"2005","unstructured":"Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS et\u00a0al (2005) Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N\u00a0Engl J Med 353(1):46\u201357. \n                    https:\/\/doi.org\/10.1056\/NEJMoa043175","journal-title":"N Engl J Med"},{"issue":"1","key":"99_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1161\/CIRCRESAHA.116.308811","volume":"119","author":"H Tavori","year":"2016","unstructured":"Tavori H, Christian D, Minnier J, Plubell D, Shapiro MD, Yeang C et\u00a0al (2016) PCSK9 association with lipoprotein(a). Circ Res 119(1):29\u201335. \n                    https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308811","journal-title":"Circ Res"},{"issue":"2","key":"99_CR8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2015.08.021","volume":"242","author":"AH Nave","year":"2015","unstructured":"Nave AH, Lange KS, Leonards CO, Siegerink B, Doehner W, Landmesser U et al (2015) Lipoprotein (a) as a\u00a0risk factor for ischemic stroke: a\u00a0meta-analysis. Atherosclerosis 242(2):496\u2013503","journal-title":"Atherosclerosis"},{"key":"99_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy902","author":"A Langsted","year":"2019","unstructured":"Langsted A, Kamstrup PR, Nordestgaard BG (2019) High lipoprotein(a) and high risk of mortality. Eur Heart\u00a0J. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehy902","journal-title":"Eur Heart J"},{"key":"99_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-018-0303-2","author":"YX Cao","year":"2018","unstructured":"Cao YX, Liu HH, Li S, Li JJ (2018) A Meta-analysis of the effect of PCSK9-monoclonal antibodies on circulating lipoprotein (a) levels. Am J Cardiovasc Drugs. \n                    https:\/\/doi.org\/10.1007\/s40256-018-0303-2","journal-title":"Am J Cardiovasc Drugs"},{"issue":"27","key":"99_CR11","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","volume":"39","author":"GF Watts","year":"2018","unstructured":"Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM et al (2018) Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart\u00a0J 39(27):2577\u20132585. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehy122","journal-title":"Eur Heart J"},{"key":"99_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy862","author":"LCA Stiekema","year":"2018","unstructured":"Stiekema LCA, Stroes ESG, Verweij SL, Kassahun H, Chen L, Wasserman SM et al (2018) Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin\/kexin type 9 antibody treatment. Eur Heart\u00a0J. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehy862","journal-title":"Eur Heart J"},{"issue":"48","key":"99_CR13","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","volume":"37","author":"PM Moriarty","year":"2016","unstructured":"Moriarty PM, Parhofer KG, Babirak SP, Cornier MA, Duell PB, Hohenstein B et\u00a0al (2016) Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart\u00a0J 37(48):3588\u20133595. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehw388","journal-title":"Eur Heart J"},{"issue":"10106","key":"99_CR14","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","volume":"390","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R et al (2017) Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a\u00a0prespecified secondary analysis of the FOURIER trial. Lancet 390(10106):1962\u20131971. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(17)32290-0","journal-title":"Lancet"},{"key":"99_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037184","author":"ML O\u2019Donoghue","year":"2018","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I et al (2018) Lipoprotein(a), PCSK9 inhibition and cardiovascular risk: insights from the FOURIER trial. Circulation. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037184","journal-title":"Circulation"},{"issue":"22","key":"99_CR16","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R et\u00a0al (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N\u00a0Engl J Med 379(22):2097\u20132107. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1801174","journal-title":"N Engl J Med"},{"issue":"27","key":"99_CR17","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1093\/eurheartj\/ehy334","volume":"39","author":"R Verbeek","year":"2018","unstructured":"Verbeek R, Hoogeveen RM, Langsted A, Stiekema LCA, Verweij SL, Hovingh GK et al (2018) Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a\u00a0primary prevention setting. Eur Heart\u00a0J 39(27):2589\u20132596. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehy334","journal-title":"Eur Heart J"},{"issue":"10155","key":"99_CR18","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","volume":"392","author":"P Willeit","year":"2018","unstructured":"Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR et al (2018) Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet 392(10155):1311\u20131320. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(18)31652-0","journal-title":"Lancet"},{"issue":"3","key":"99_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/MOL.0000000000000171","volume":"26","author":"C Yeang","year":"2015","unstructured":"Yeang C, Witztum JL, Tsimikas S (2015) \u2018LDL-C\u2019 = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin\/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol 26(3):169\u2013178","journal-title":"Curr Opin Lipidol"},{"issue":"24","key":"99_CR20","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","volume":"128","author":"J Leebmann","year":"2013","unstructured":"Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D et al (2013) Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 128(24):2567\u20132576. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.002432","journal-title":"Circulation"},{"issue":"9","key":"99_CR21","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","volume":"36","author":"E Roeseler","year":"2016","unstructured":"Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P et al (2016) Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization. Arterioscler Thromb Vasc Biol 36(9):2019\u20132027. \n                    https:\/\/doi.org\/10.1161\/ATVBAHA.116.307983","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10057","key":"99_CR22","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","volume":"388","author":"NJ Viney","year":"2016","unstructured":"Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ et al (2016) Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388(10057):2239\u20132253. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)31009-1","journal-title":"Lancet"}],"container-title":["Clinical Research in Cardiology Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11789-019-00099-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11789-019-00099-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11789-019-00099-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:15:22Z","timestamp":1583280922000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11789-019-00099-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,5]]},"references-count":22,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["99"],"URL":"https:\/\/doi.org\/10.1007\/s11789-019-00099-z","relation":{},"ISSN":["1861-0706","1861-0714"],"issn-type":[{"value":"1861-0706","type":"print"},{"value":"1861-0714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,5]]},"assertion":[{"value":"5 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"U.\u00a0Julius: honoraria from Aegerion, Akcea, Amgen, Amryt, Chiesi, Sanofi, Kaneka, Diamed, Fresenius Medical Care, MSD. S.\u00a0Tselmin received honoraria for lectures and consulting by Amgen, Fresenius Medical Care, Kaneka, MSD, and Sanofi-Aventis. S.\u00a0Fischer: honoraria from Sanofi, Amgen, MSD, Berlin-Chemie, Abbott, Boehringer Ingelheim. U.\u00a0Schatz and S.\u00a0R.\u00a0Bornstein declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}